Need Help?
Give us a call at (833)928-4437
ANCHOR MOLECULAR · RESEARCH MATRICES
Build your controls.
Keep the plasma background.
Move beyond a buffer-only starting point. Anchor Molecular DNA-Depleted EDTA Plasma provides a human-plasma base for preparing your own research reference materials—with reduced endogenous DNA and retained matrix components.
Less background DNA
Typical DNA specification: <20 pg/mL, for a low-background starting matrix.
Human EDTA plasma
Pooled human-plasma matrix, rather than buffer or a synthetic plasma substitute.
Five orderable formats
Four bulk volumes plus forty 5 mL vials. Choose the supplied format in the ordering chart.
The matrix is part of the test.
Adding DNA to buffer and adding DNA to plasma are not the same starting point. Proteins, lipids and other plasma components can influence an extraction workflow. A DNA-depleted plasma matrix lets you introduce your material of interest while working in a human-plasma background.
Buffer offers a simpler background.
DNA-depleted plasma retains a complex human-plasma background.
Illustrations explain the concept only: blue = added DNA, gold = proteins, green = lipids. Not measured data, not to scale; the number of symbols does not represent composition or concentration.
DNA depletion does not mean a stripped-down matrix.
The point is not simply to remove background DNA. It is to work with a plasma background that still contains other naturally occurring material. Anchor’s microscopy comparison shows structures it identifies as exosomes and non-exosomal vesicles or aggregates in both normal and DNA-depleted plasma.
Normal plasma
DNA-depleted plasma
Manufacturer microscopy, presentation slide 3. Original image panels are shown with permission. These images do not establish a lot-specific exosome concentration or universal equivalence for every application.
Your spike-in material changes the question.
A synthetic DNA spike and a fragmented genomic-DNA preparation need not behave identically during extraction. Anchor’s study compares both across buffer, synthetic plasma, plasma and DNA-depleted plasma.
The pattern changes between the two types of input material. When planning a research control, consider both the matrix and the kind of DNA you introduce—not just the nominal starting concentration.
Look beyond yield to repeatability.
For a low-level research assay, average recovery is only one part of the picture. Variation between replicates matters too. Anchor’s example plots the standard deviation of calculated allele frequency against allele frequency for four matrix conditions.
Plasma and DNA-depleted plasma show greater variation than buffer at the displayed levels. A simpler buffer background can therefore give a different view of assay behavior. Use a matrix suited to the research question, then establish acceptance criteria in your own workflow.
These are manufacturer study results, not guaranteed precision, sensitivity or detection limits for this product.
Put the matrix to work in your research.
01 / PREPARE
Build your own reference materials
Introduce your own high-positive research material into a plasma base to prepare study-specific controls, rather than relying on buffer alone.
02 / EXTRACT
Evaluate the extraction step
Use a plasma background when studying how your workflow handles a complex matrix. Confirm suitability for your target, extraction method and detection system.
03 / EVALUATE
Study low-level DNA detection
Reduced endogenous DNA provides a useful starting matrix for cfDNA and ctDNA assay-development research. It is not a pre-assigned positive control.
See why the background matters.
In the manufacturer’s example, equal amounts of ctDNA fragments were serially spiked into four matrices: TE buffer, synthetic plasma, patient plasma and DNA-depleted plasma. Extracted ctDNA was then quantified by qPCR.
The curves differ by matrix. That is the buying insight: a buffer-based result may not describe how the same workflow behaves in plasma.
Read this as a matrix comparison—not a product-quality ranking. The figure describes one manufacturer experiment, not guaranteed recovery, patient-sample equivalence or universal assay performance.
Manufacturer data: “Matrix Effect of ctDNA Extraction,” reproduced from the DNA-Depleted Plasma brochure. Axes and plotted data are unchanged.
Read the trace—not just the total fluorescence.
Anchor’s Figure A compares DNA-fragment fluorescence profiles in buffer and plasma. The prominent short-fragment peaks are similar, while the plasma trace shows more signal across the higher-size region. The practical lesson is that the surrounding matrix deserves attention—not just the main peak.
RFU is a fluorescence signal, not a direct statement of genomic DNA mass. Anchor’s later analytical memo reports protein-related high-molecular-weight signals after bead-based cfDNA extraction. Read these sources together: a higher-size feature is not, by itself, proof of residual DNA.
Choose the format around your bench—not just the volume.
Four bulk-volume choices
Select 50, 100, 500 or 1,000 mL for the total volume your study needs. These are listed volume formats; do not assume a specific bottle count.
Forty separate 5 mL vials
Catalog 60601005 supplies 40 × 5 mL: 200 mL total. Consider this presentation when separate small containers suit your handling plan.
One order quantity is one listed format. For example, quantity 1 of 60601005 means forty 5 mL vials—not one vial. The live ordering chart above identifies each catalog number and its supplied quantity.
Know what is in the matrix. Know what is in the signal.
Product characterization
The insert lists typical DNA, protein, immunoglobulin, lipid and pH characteristics. See the Specifications tab for the insert’s values, kept separate from lot-specific results.
A lot-specific certificate
The manufacturer states that the order’s COA is enclosed in the shipping package. The downloadable example is lot 240636 only; it is not the certificate for a future shipment.
A practical analytical detail: Anchor’s research memo investigates a high-molecular-weight feature seen after bead-based cfDNA extraction. In the experiments described, the feature persisted after DNase treatment but was removed by proteinase K, supporting a protein-related contribution to the observed signal.
If you use fluorescence-based DNA quantification, account for workflow-specific interference rather than interpreting every signal as residual DNA. Review the memo with your method-development team; it is not a universal treatment protocol.
Plan for cold storage and responsible handling.
This is human-derived laboratory material. Treat it as potentially biohazardous, even when donor-screening results are negative, and use the controls required by your laboratory’s risk assessment.
Keep the applicable label, product insert, SDS and lot COA with your study records. The SDS specifies frozen storage for unopened bottles and refrigerated handling after opening; follow the current supplied instructions and lot expiration. The insert identifies blue-ice shipment, not a guaranteed dispatch or delivery time.
The SDS lists sodium azide in a 0–0.05% range. Check the applicable product documentation when assessing formulation compatibility and waste disposal. For in vitro research use only—not for diagnostic or therapeutic use.
Round out the research workflow.
Organize research aliquots with MTC Bio cryogenic vials and keep samples organized with MTC Bio freezer boxes. These are related workflow supplies, sold separately—not included with this plasma or validated as part of Anchor’s assay data.
Need a different background-DNA level?
Anchor lists customized plasma and less-processed material with higher background DNA as options available on request. Ask Blue Tiger Scientific about your research requirements. Those alternatives are separate from the five standard DNA-depleted formats shown here and require confirmation of specification and availability.
Frequently Asked Questions
What is DNA-depleted EDTA plasma?
It is a pooled human-plasma matrix processed to reduce endogenous DNA while retaining other plasma components. Anchor Molecular supplies it for in vitro research applications, including preparation of study-specific reference materials.
Is DNA-depleted plasma completely DNA-free?
No absolute-zero claim is made. The manufacturer’s product insert gives a typical DNA value below 20 pg/mL. The SDS also notes trace unencapsulated DNA; suitability depends on your target and method.
Why choose a plasma matrix rather than buffer?
Buffer is a simpler background. Human plasma contains proteins, lipids and other components that can affect extraction and downstream measurement. Anchor’s brochure shows matrix-dependent ctDNA extraction in its example experiment; it does not establish universal equivalence to patient samples.
What is included in catalog 60601005?
One listed pack contains forty 5 mL vials of DNA-depleted plasma, totaling 200 mL. An order quantity of one means one 40-vial pack. The 50, 100, 500 and 1,000 mL formats are separate catalog numbers.
Does the bottle photograph show exactly what I receive?
The photograph shows representative Anchor Molecular DNA-Depleted Plasma bottles labeled 100 mL, catalog 60601003. It illustrates the product, not a three-bottle order. Your supplied volume and vial count follow the catalog number selected in the ordering chart.
Will I receive a certificate of analysis?
Anchor states that the COA for the order is enclosed in the shipping package. The downloadable sample is for lot 240636 and must not be treated as the certificate for every shipment. Its reported RNaseP qPCR gDNA result is lot-specific.
How should DNA-depleted plasma be stored and handled?
Follow the current supplied label, lot COA, product insert and SDS. The SDS states unopened bottles are stored at −20°C or below and opened bottles are stable up to 30 days at 2–8°C. The insert and sample COA also describe refrigerated use storage; confirm the instructions applicable to your lot. Treat all human-derived material as potentially biohazardous.
Is this a ready-to-use diagnostic control or a positive DNA standard?
No. It is a research-use plasma matrix, not a diagnostic product or an assigned positive DNA standard. Any spike-in material, target concentration, extraction method and acceptance criteria must be established for the laboratory’s research workflow.
Use this text to share information about your product.
Use this text to share information about your product.
Use this text to share information about your product.